证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2023-012 □√特定对象调研 □分析师会议 □√券商策略会 投资者关系活 □媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □现场参观 □其他（线上会议、电话会议） | --- | --- | --- | --- | --- | --- | --- | |--------------|-----------------|----------|----------|----------|----------|----------| | | 民生加银基金 | 华泰证券 | 六禾基金 | 长信基金 | 银华基金 | 天弘基金 | | 参与单位名称 | 鲍尔赛嘉投资 | 华夏基金 | 兴银理财 | 兴业基金 | 观火投研 | 翊安投资 | | 及人员姓名 | 优益增投资 | 上海涌津 | 兴业自营 | 太平资产 | 鹏扬基金 | 诺德基金 | | | 仙人掌基金 | 华创证券 | | | | | | 时间 | 2023 年 6 月 27 | 日 | | | | | ...

证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司 投资者机构调研活动记录表 编号：2023-011 □√特定对象调研 □分析师会议 投资者关系活□媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □√现场参观 □券商策略会 □其他（线上会议、电话会议） 参与单位名称 | --- | --- | --- | --- | |--------------|------------------------------------|-------|----------| | | 银华基金 | | 中泰证券 | | 及人员姓名 | | | | | 时间 | 2023 年 6 月 7 日 | | | | 地点 | 贵州省贵阳市乌当区高新北路 | 3 | | | 上市公司接待 | 董事、副总经理、董事会秘书：王光平 | | | 人员姓名 证券总监、证券事务代表：王伟 投资者问答： 问题一、公司二季度销售情况如何？ 答：根据公司销售数据显示，从今年 2 月份以来，市场销售已开始恢 复，目前已基本恢复至年度正常水平，预计三、四季度也将保持相对稳定的 投资者关 ...

证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2023-010 □√特定对象调研 □√分析师会议 投资者关系活□媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □现场参观 □券商策略会 □其他（线上会议、电话会议） | --- | --- | --- | --- | --- | --- | |--------------|-------------------|------------------------|--------------------|---------------------|--------------| | | 上投摩根 | 鹏扬基金 | 财通基金 | 财通资管 东方红资管 | | | | 农银汇理 富国基金 | | 长信基金 | 银河基金 | 西部利得基金 | | 参与单位名称 | | | | | | | | 中泰证券 | | 泰信基金 永赢基金 | 申万菱信基金 | 中信保诚基金 | | 及人员姓名 | | | | | | | | | | | 山西证券 | 开源证券 | | | 光 ...

证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2023-009 □√特定对象调研 □分析师会议 □√券商策略会 投资者关系活□媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □现场参观 □其他（线上会议、电话会议） | --- | --- | --- | --- | --- | --- | |--------------|-----------------|-------|-----------------------|-------------------|--------------| | | 工银瑞信基金 | | 平安资管 泰康养老保险 | 中邮基金 渤海人寿 | | | | 建信基金 | | | | 中信建投资管 | | 参与单位名称 | | | | 银华量化 兴合基金 | | | 及人员姓名 | 盘京投资 | | | | | | | | | | 德邦证券 华创证券 | | | | 坤泰九盈投资 | | | | | | 时间 | 2023 年 5 月 23 | 日 | | | | | | | | 1 ...

编号：2023-008 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □√业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（线上会议、电话会议） | | 参与单位名称 | 通过线上参与"2022 年度贵州辖区上市公司业绩说明会暨投资者集体接待日 | | 及人员姓名 | 活动"的投资者 | | 时间 | 年 月 日 2023 5 17 15:30-17:00 | | 地点 | "全景路演"网络平台（http://rs.p5w.net） | | 上市公司接待 | 副董事长、副总经理：王金华 | | 人员姓名 | 董事、副总经理、董事会秘书：王光平 | | | 财务总监：曾志辉 | | | 投资者问答： 问题一、贵州 74 个项目拟获省级专项资金支持，名单中有公司吗？能带 | | | 来哪些利好？ | | | 答：您好，公司是国家高新技术企业，同时也是贵州省"专精特新"企 | | 投资者关系活 | 业，正在申报"小巨人"科技企业。在持续经营周期里，在产品研发、贴 | | 动主要内容介 | 息、技改等方面，都 ...

Group 1: Marketing Strategy and Goals - The company is reforming its marketing system to enhance efficiency and effectiveness, aiming for a significant impact on Q2 performance [2][3] - The marketing reform includes structural adjustments, team building, product and market strategies, brand promotion training, and employee assessment incentives [2][3] - The goal is to increase the revenue share from OTC channels and enhance the company's brand value in women's health management [3] Group 2: Research and Development Initiatives - The company focuses on clinical value in R&D, particularly in gynecology, aligning new product pipelines with existing market resources [3][4] - A comprehensive R&D system has been established, covering the entire process from drug discovery to post-market evaluation [3][4] - There is a commitment to significantly increase R&D expenditure and expand the R&D team to enhance capabilities and efficiency [3][4] Group 3: Financial Performance and Market Positioning - The company aims to create 2-3 major products exceeding 500 million CNY in revenue within the next 3-5 years, alongside multiple products generating over 100 million CNY [4] - The strategy includes expanding coverage in essential drug markets and leveraging leading products to drive market growth [4] - The company anticipates a more stable revenue structure from its main products, supported by a solid foundation from secondary products [4] Group 4: Future Growth and Strategic Investments - The company is preparing for the national market launch of traditional Chinese medicine formula granules, focusing on technological advancement and market strength [5] - Investment in Huylun Pharmaceutical is expected to yield significant positive impacts and enhance the company's strategic positioning in the small molecule drug sector [5] - The company plans to implement a new round of equity incentive plans based on performance targets and growth expectations [5]

证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |------------|-------------------|-------------------|-----------|----------|-------------------| | | | | | 编号： | 2023-006 | | | | | | | | | 投资者关系 | | | | | | | 活动类别 | □新闻发布会 | | □路演活动 | | | | | □现场参观 | | | | | | | | | | | | | | | | | | | | | | | | 诺德基金 | 西部利得基金 | | | | | | | | | | 泰康保险 | | | | | | | | | | 汇添富 | 景顺基金 | | 参与单位名 | | | | | 涌津投资 | | 称及人员姓 | 金百镕投资 | | | | | | 名 | | | | | 高毅资管 | | | | | | | 华宝 ...

Financial Performance - The company's revenue for Q1 2023 was ¥208,755,879.11, a decrease of 16.24% compared to ¥249,216,213.05 in the same period last year[4] - Net profit attributable to shareholders was ¥25,092,336.81, down 18.74% from ¥30,879,340.57 year-on-year[4] - Basic earnings per share decreased to ¥0.1082, down 18.89% from ¥0.1334 in the same period last year[4] - Total operating revenue for Q1 2023 was CNY 208,755,879.11, a decrease of 16.3% compared to CNY 249,216,213.05 in Q1 2022[15] - Net profit for Q1 2023 was CNY 25,092,336.81, down 18.7% from CNY 30,879,340.57 in the same period last year[16] - Basic earnings per share decreased to CNY 0.1082 from CNY 0.1334, reflecting a decline of 18.5%[17] Cash Flow - The net cash flow from operating activities was -¥311,487.89, a decline of 108.43% compared to ¥3,695,741.81 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 311,487.89, compared to a net inflow of CNY 3,695,741.81 in Q1 2022[17] - The net cash flow from financing activities increased by 36.75% to ¥50,602,908.34, primarily due to increased bank borrowings[7] - The net cash flow from financing activities was 50,602,908.34 CNY, compared to 37,005,120.20 CNY in the previous year[18] - The net cash flow from investment activities was -34,345,766.82 CNY, compared to a net cash flow of 31,179,154.70 CNY in the previous year[18] - The net increase in cash and cash equivalents was 15,945,653.63 CNY, down from 71,880,016.71 CNY year-over-year[18] - The ending balance of cash and cash equivalents was 116,613,200.61 CNY, compared to 144,358,114.14 CNY at the end of the previous year[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,902,558,635.90, an increase of 3.18% from ¥1,843,850,779.14 at the end of the previous year[4] - Total assets amounted to ¥1,902,558,635.90, up from ¥1,843,850,779.14, indicating an increase of about 3.2%[13] - Total liabilities increased to ¥747,021,674.97 from ¥714,648,981.41, a rise of approximately 4.5%[13] - The company reported a total of ¥1,263,779,120.13 in non-current assets, an increase from ¥1,229,856,973.52, reflecting a growth of approximately 2.7%[13] - The company’s total equity is reported at ¥1,155,536,960.93, showing a slight increase from the previous period[13] Shareholder Information - Total number of common shareholders at the end of the reporting period is 25,325[9] - The company has a total of 80,187,166 shares held by the largest shareholder, accounting for 34.57% of total shares[9] Expenses and Costs - Total operating costs decreased by 14.6% to CNY 183,519,448.53 from CNY 214,995,242.32 year-over-year[15] - The company reported a decrease in sales expenses to CNY 100,210,367.91 from CNY 121,925,070.24, reflecting cost management efforts[15] - Research and development expenses increased to CNY 3,990,027.82, up from CNY 3,589,480.60, indicating a focus on innovation[15] Tax and Government Subsidies - The company reported a significant increase in tax payable by 121.69%, reaching ¥13,154,202.38 due to higher VAT, property tax, and land use tax[7] - The company received government subsidies amounting to ¥1,116,830.60, which are closely related to its normal business operations[6] Other Information - The company recorded an asset impairment loss of -¥383,350.04, which is a 116.47% increase compared to -¥177,095.25 in the previous year[7] - The first quarter report was not audited[19] - The report was released by the board of directors on April 27, 2023[20] - The company did not report any significant new product launches or market expansions during this quarter[16] - There were no acquisitions or mergers reported in the current quarter[16]

债券代码：128091 债券简称：新天转债 证券代码：002873 证券简称：新天药业 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2023-005 | | □特定对象调研 □分析师会议 □媒体采访 □√业绩说明会 | | --- | --- | | 投资者关系活 | | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称 | 通过线上参与公司 年度业绩网上说明会的投资者 2022 | | 及人员姓名 | | | 时间 | 年 月 日 2023 4 12 15:00-17:00 | | 地点 | 深圳证券交易所"互动易"平台、"新天药业投资者关系"微信小程序 | | | 董事长、总经理：董大伦先生 | | 上市公司接待 | 董事、副总经理、董事会秘书：王光平先生 | | 人员姓名 | 财务总监：曾志辉女士 | | | 独立董事：官峰先生 | | | 问题 1、您好，领导，促进公司发展的有利因素很多，那我想咨询一下，公 | | | 司认为哪些方面制约公司业务，谢谢。 | | | 答：第一，企业经营发展优势暨保持稳健可持续增长，已经具备以下几个 | ...

关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）2022 年年度报告及其摘 要已经第七届董事会第七次会议审议通过。具体内容详见公司指定信息披露媒体 《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）于 2023 年 3 月 28 日发 布的《2022 年年度报告摘要》（公告编号：2023-013），《2022 年年度报告》 （公告编号：2023-012）同日发布于巨潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者进一步了解公司生产经营情况，公司定于 2023 年 4 月 12 日（星期三）下午 15:00-17:00 在深圳证券交易所"互动易"平台及"新天药业 投资者关系"微信小程序同步举行 2022 年度业绩网上说明会。本次年度业绩说 明会采用网络远程的方式举行，投资者可通过以下两种方式参与互动交流，具体 如下： | 证券代码：002873 | 证券简称：新天药业 | 公告编号：2023-022 | | --- | ...